Diego Díaz-García, Obrixtamig

Diego A. Díaz García: Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutant advanced NSCLC whose DP on 1L osimertinib

Diego A. Díaz García, Medical Oncologist /CEO/Founder at CánCare – High Specialty in Oncology, shared on X:

“ORCHARD: Osimertinib plus datopotamab deruxtecan in patients with EGFRm aNSCLC whose DP on 1L osimertinib.

ORR: Osi + Dato-Dxd 4mg (ODd4) 43%, Osi + Dato-Dxd 6mg (ODd6) 36%.
Median PFS 9.5m and 11.7m , 12m PFS 21% % 39%.

  1. TROPION-Lung14 Dato-Dxd + osimertinib as 1L tx for adv nsqNSCLC EGFRmut
  2. TROPION-Lung15 Dato-Dxd +- osimertinib for adv EGFRm nsqNSCLC after PD on osimertinib.”
cancer Diego A. Díaz García EGFRm NSCLC OncoDaily Oncology